Daily Archives: September 22, 2021

Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform

CoolSeal receives CE mark, Japan PMDA approval; now available in over 20 countries worldwide

LOUISVILLE, COLORADO, Sept. 22, 2021 (GLOBE NEWSWIRE) — Bolder Surgical today announced the global launch of its CoolSeal™ Vessel Sealing platform. CoolSeal has been in use since October 2020 in the U.S., and with the new international regulatory approvals the devices are available in over 20 countries around the world.

Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications.

The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector. Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology.

“Having successfully used the 3 mm vessel sealer for many cases in pediatric surgery, the Trinity 5 mm device is an excellent addition to my selection of surgical instruments,” said Dr. Satoshi Ieiri, pediatric surgeon, Kagoshima University Hospital. “The slim, curved jaw design and added sealing capacity supports procedures on larger children, adolescents and adults. It is a true all-in-one instrument that enables precise dissection and produces quick sealing times with minimal thermal distribution and great advantages.”

With an average thermal spread less than 1 mm and slim, dual action jaws, CoolSeal devices combine the finesse of true surgical instruments with the gold-standard efficacy of advanced bipolar RF vessel sealing. The devices are designed for multi-functional performance that can mean fewer instrument exchanges, helping streamline workflow and reduce operative time.

Bolder Surgical continues its path of innovation through focused investment in R&D to move the company beyond its origin in pediatric devices.  “We’ve successfully leveraged our expertise in microsurgical devices and energy delivery to create the CoolSeal portfolio,” stated Robert Kline, President and CEO of Bolder Surgical. “The portfolio is designed to give surgeons innovative, versatile options that minimize surgical impact, from the smallest patients to adolescents and adults. We are extremely proud that physicians across the globe can now access this innovative technology.”

CoolSeal products are now available in over 20 countries worldwide including member countries of the European Union, the United Kingdom, Japan, Australia, and the Middle East. For information visit BolderSurgical.com.

Attachment

Tricia Strong
Bolder Surgical
719 433 4836
tstrong@boldsurg.com

Laserfiche Announces Launch of Cloud Document Management and Process Automation Solution to EMEA Region, Supports Digital Resiliency Strategies

LONDON, Sept. 22, 2021 /PRNewswire/ — Laserfiche today announced the availability of Laserfiche Cloud in the Europe, Middle East and Africa (EMEA) region. The leading SaaS provider of intelligent content management and business process automation’s cloud offering delivers an innovative and trusted system for securely managing content and automating business processes across the enterprise. With digital workflows, […] read more

Adagio Therapeutics informa sobre o Programa de Anticorpos COVID-19, bem como sobre os Destaques de Negócios e Resultados Financeiros do Segundo Trimestre de 2021

Novos Dados que Corroboram o Potencial do ADG20 para o Tratamento e Prevenção da COVID-19 Serão Divulgados na IDWeek 2021 Número de Pacientes do Ensaio Clínico da Fase 2/3 do EVADE Global de ADG20 Expandido após Avaliação IDMC Conclusão da IPO de US$355,8 milhões para financiar o avanço contínuo do portfólio de soluções com base […] read more

Adagio Therapeutics apporte des mises à jour du programme d’anticorps contre la COVID-19, et révèle les récents faits marquants de son activité et les résultats financiers du deuxième trimestre 2021

De nouvelles données étayant le potentiel de l’ADG20 pour le traitement et la prévention de la COVID-19 seront présentées lors de l’IDWeek 2021 La population de patients participant à l’essai clinique mondial EVADE de phase 2/3 de l’ADG20 a été élargie suite à l’évaluation de l’IDMC Une introduction en bourse de 355,8 millions de dollars a […] read more

W. L. Gore & Associates améliore le portefeuille d’endoprothèses GORE® VIABAHN® avec la pose d’un profil plus bas

Les améliorations apportées aux dispositifs de grand diamètre comprennent l’accessibilité par des gaines plus petites tout en permettant une meilleure visualisation grâce à l’ajout de marqueurs radio-opaques 25 ans d’innovation continue PUTZBRUNN, Allemagne, 22 septembre 2021 /PRNewswire/ — Dans le cadre de ses efforts pour améliorer continuellement les solutions médicales pour les patients souffrant de maladies […] read more

W. L. Gore & Associates Enhances GORE® VIABAHN® Endoprosthesis Portfolio With Lower Profile Delivery

Improvements to large diameter devices include accessibility through smaller sheaths while providing enhanced visualization by adding radiopaque markers 25 years of continued innovation PUTZBRUNN, Germany, Sept. 22, 2021 /PRNewswire/ — As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced the EMEA […] read more